Research Article
Secondary Pharmacotherapeutic Prevention among German Primary Care Patients with Peripheral Arterial Disease
Table 3
Number of selected pharmacotherapeutical prescriptions in a 3-year study group of PAD and CVD patients by means of ATC classification.
| | PAD () | CVD () | value |
| | Total number, mean (SD) | | | n.s. | | ATC groups level 1 | | | | | A alimentary tract and metabolism | 322 (67.2%) | 618 (64.5%) | n.s. | | B blood and blood forming organs | 318 (66.4%) | 615 (64.2%) | n.s. | | C cardiovascular system | 405 (84.6%) | 849 (88.6%) | <.05 | | ATC groups level 2 | | | | | A 10 antidiabetic agents | 135 (28.2%) | 194 (20.3%) | <.001 | | B 01 antithrombotic agents | 303 (63.3%) | 584 (61.0%) | n.s. | | C 01 cardiac therapy agents | 101 (21.1%) | 354 (37.0%) | <.0001 | | C 07 β-blockers | 240 (50.1%) | 635 (66.2%) | <.0001 | | C 08 calcium channel blockers | 140 (29.2%) | 233 (24.3%) | <.05 | | C 09 renin-angiotensin system agents | 322 (67.2%) | 656 (68.5%) | n.s. | | C 10 antihyperlipidemics | 241 (50.3%) | 536 (55.9%) | <.05 | | ATC groups level | | | | | A 10A insulins and analogues | 60 (12.5%) | 77 (8.0%) | <.05 | | A 10B oral blood glucose lowering agents | 96 (20.0%) | 156 (16.3%) | n.s. | | B 01AA Vitamin K antagonists | 56 (11.7%) | 124 (12.9%) | n.s. | | B 01AB heparin and derivates | 50 (10.4%) | 97 (10.1%) | n.s. | | B 01AC platelet aggregation inhibitors | 254 (53.0%) | 481 (50.2%) | n.s. | | C 09AA ACE inhibitors, plain | 198 (41.3%) | 439 (45.8%) | n.s. | | C 10AA HMG CoA reductase inhibitors | 222 (46.3%) | 504 (52.6%) | <.05 | | ATC groups level 5 | | | | | B 01AC04 clopidogrel | 101 (21.1%) | 186 (19.4%) | n.s. | | B 01AC06 acetylsalicylic acid | 206 (43.0%) | 420 (43.8%) | n.s. | | B 01AC23 cilostazol | 0 (0.0%) | 0 (0.0%) | n.s. | | C 09AA05 ramipril | 139 (29.0%) | 310 (32.4%) | n.s. | | C 10AA01 simvastatin | 195 (40.7%) | 443 (46.2%) | <.05 |
|
|
